Home / Stocks / Molbio Diagnostics Ltd
MOLBIO

Molbio Diagnostics Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,526.4

Change

+28.8 (1.92%)

Open

₹1,505.0

Prev. Close

₹1,497.6

Day High

₹1,540.2

Day Low

₹1,477.0

Volume Analysis

Traded

463,324

Delivered

117,563

Delivery %

25.37%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (22.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (120.4%)
  • •Strong 3-year revenue growth (64.1%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,615.26 ₹1,577.73 ₹1,552.06 ₹1,514.53 ₹1,488.86 ₹1,451.33 ₹1,425.66
Fibonacci ₹1,577.73 ₹1,553.59 ₹1,538.67 ₹1,514.53 ₹1,490.39 ₹1,475.47 ₹1,451.33
Camarilla ₹1,543.78 ₹1,537.99 ₹1,532.19 ₹1,514.53 ₹1,520.61 ₹1,514.81 ₹1,509.02

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+9.49%

1 Month

+15.41%

3 Months

+38.96%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹62.3

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

5.06%

Net margin 11.34% × asset turnover 0.36x × equity multiplier 1.24x

Company Overview

Sector

Healthcare

Market Cap

₹17,111 Cr

P/E (TTM)

236.0

ROE

15.6%

Book Value

₹125.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Molbio Diagnostics Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%). Strong 3-year EPS growth (120.4%).

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

53

Valuation

0

Cash Flow

5

Corporate Governance

50

Momentum

74

Institutional Ownership

30

Business Quality

76

Risk & Volatility

63

Liquidity

50

From Screener.in

  • +Company's working capital requirements have reduced from 148 days to 116 days
  • −Stock is trading at 11.9 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026

Submission of Newspaper Adverstisement of Un-audited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026

CRISIL report shows IPO proceeds utilized as planned for capex; no deviations for quarter ended September 30, 2026.

Audio recording of earnings call for Q2 and H1 FY2026-27 results made available on website.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2025 Sep 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 100 580 561 408 259
Expenses + 116 413 402 308 215
Operating Profit -16 167 159 101 44
OPM % -16.16% 28.86% 28.31% 24.63% 16.97%
Other Income + 1 1 5 3 6
Interest 4 7 12 11 9
Depreciation 12 14 20 17 23
Profit before tax -31 148 132 76 18
Tax % -23.43% 27.68% 27.32% 30.53% 56.0%
Net Profit + -24 107 96 53 8
EPS in Rs -2 10 8 5 1
Raw PDF — — — — —
YoY Sales growth — — — 310 -55

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026
Sales + 1,271 776 327 837 1,020 1,446
Expenses + 676 457 286 602 760 1,126
Operating Profit 595 319 40 234 260 320
OPM % 47.0% 41.0% 12.0% 28.0% 26.0% 22.0%
Other Income + 1 5 8 -49 -4 9
Interest 35 25 6 14 18 33
Depreciation 12 42 19 41 45 64
Profit before tax 549 258 23 130 194 231
Tax % 25.0% 27.0% 32.0% 36.0% 29.0% 29.0%
Net Profit + 410 187 16 84 139 164
EPS in Rs 36 17 1 9 13 15
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth — -39 -58 — 22 42

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 333 681 737 821 966 1,158 1,429
Borrowings + 257 105 57 184 147 450 390
Other Liabilities + 215 85 123 211 346 496 498
Total Liabilities 806 874 920 1,218 1,461 2,115 2,329
Fixed Assets + 55 182 189 289 290 536 520
CWIP 100 0 0 2 27 11 18
Investments 9 9 54 6 46 6 6
Other Assets + 643 683 676 921 1,099 1,562 1,785
Total Assets 806 874 920 1,218 1,461 2,115 2,329
Equity Capital 2 2 2 2 2 11 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 344 98 68 10 287 50
Cash from Investing Activity + -142 -87 -51 -45 -123 -54
Cash from Financing Activity + -192 -20 31 -32 -26 276
Net Cash Flow 10 -9 48 -67 138 273
Free Cash Flow 212 35 55 -7 232 1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 78 53 251 23 141 38

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

  Sep 2026
Public 38.04%
Promoters 41.29%
FII 1.59%
DII 19.09%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Molbio Diagnostics Ltd (this stock) 17,111 236.0 11.89 15.6%
Poly Medicure Limited 17,041 53.9 5.22 9.8%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Pfizer Ltd 17,601 115.0 12.74 19.8%
Alivus Life Sciences Ltd 17,803 50.6 — —
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%

Which Mutual Funds Hold Molbio Diagnostics Ltd?

Frequently Asked Questions about Molbio Diagnostics Ltd

Community Sentiment

What are other investors saying about Molbio Diagnostics Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.